Outlook Good For 7 Drugs Up For Q3 Review

This report provides an in-depth analysis of 24 key catalysts related to drugs, medical devices, diagnostics, and deals anticipated in Q3 2024. For each drug, we offer a detailed assessment of the likelihood of success at various stages, including Phase reviews and PDUFA evaluations, as well as the overall Likelihood of Approval (LOA). These insights are based on a robust dataset that combines Pharmapremia—Citeline’s drug development benchmarking tool—and Biomedtracker’s LOA data. This powerful combination supports informed decision-making in drug pipeline prioritization, partnerships, acquisitions, and other strategic areas.

Additionally, we leverage Biomedtracker’s comprehensive drug approval data to further enhance the accuracy of our projections. For a retrospective look, the outcomes of the catalysts featured in our Q2 2024 Outlook Report are summarized on Page 6 of this report.

Finally, we've curated a list of Large Impact catalysts expected through Q3 2024, providing readers with a forward-looking view of significant developments that could shape the industry in the near future. This report serves as an essential resource for stakeholders aiming to navigate the complexities of drug development and approval processes with greater confidence and precision.